-
Sector Analysis
![]()
Congenital Fibrinogen Deficiency Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
The Congenital Fibrinogen Deficiency (CFD) market size across the three major markets (3MM: the US, Germany, and Japan) was $673.33 million in 2021 and is expected to achieve a CAGR of more than 1% during 2021-2031. The anticipated launch of Biotest/Grifols’ BT-524 is anticipated to propel growth of the market in the coming years. BT-524 is expected to launch in 2024 in Germany, 2025 in the US, and 2027 in Japan. The CFD market research report provides an analysis of...
-
Product Insights
![]()
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hereditary Angioedema (HAE) Pipeline Drugs Development Market Overview Hereditary Angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids. The Hereditary Angioedema pipeline drugs market research report provides comprehensive information on the therapeutics under development for Hereditary Angioedema, complete with analysis by...
-
Track & Monitor
![]()
Innovation in Pharmaceuticals: Affinity chromatography for antibodies
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – Octanorm
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Octanorm Drug Details Immunoglobulin G (Human) (Octonorm)Â contains mainly normal human immunoglobulin G (IgG) with...
-
Product Insights
![]()
Chronic Lymphocytic Leukemia (CLL) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety), and weight loss. Treatment options include surgery, radiation therapy, chemotherapy, or a combination of methods. The CLL pipeline drugs market research report provides comprehensive information on the...
-
Product Insights
![]()
Systemic Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Systemic Lupus Erythematosus Pipeline Drugs Market Report Overview The inflammation triggered by Systemic Lupus Erythematosus (SLE) affects many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender, and hormones. The Systemic Lupus Erythematosus pipeline market research report provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route...
-
Sector Analysis
![]()
Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer – August 2022
The urgent need for effective preventive vaccine and efficacious therapeutics for COVID-19 has given rise to an unprecedented pace of R&D by the biopharmaceutical industry, coupled with substantial investment by governments, non-profit agencies, and other stakeholders. There are currently more than 1,800Â assets in development for COVID-19, the majority of which are very early-stage or have little data available. The Coronavirus Disease 2019 (COVID-19) clinical and commercial analyzer report looks at the data from clinical trials for vaccines and therapeutics either...
-
Sector Analysis
![]()
Contract Injectable Packaging Trends in the Bio/Pharma Industry
Injectables and their packaging requirements are very important to marketed treatments given the volume of vaccines required to tackle the COVID-19 pandemic and the rising number of biologics in development pipelines and on the market. Most injectable drugs in the development pipeline are biologics, which will become increasingly approved and more established in the treatment landscape in the future. The top contract packaging organizations (CPOs) for injectables by the number of contracts are standalone packagers along with large CMOs which...
-
Product Insights
![]()
Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Mild Cognitive Impairment pipeline market report provides a comprehensive overview of the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive...
-
Product Insights
![]()
Obsessive-Compulsive Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The obsessive compulsive disorder pipeline market research report provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features...
-
Product Insights
![]()
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chronic inflammatory demyelinating polyneuropathy (CIDP), also called chronic relapsing polyneuropathy, is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling, and numbness of hands and feet. The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs in Development market research report provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for...
-
Product Insights
![]()
Primary Immune Deficiency (PID) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Primary immunodeficiency is defined as a weakened immune system that results in repeated infections and other health problems occurring more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea, and diarrhea. The Primary Immune Deficiency drugs in development market research report provide comprehensive information on the therapeutics under development for Primary Immune Deficiency, complete with analysis by stage of development, drug target, mechanism...
-
Product Insights
![]()
Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms, and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy. The Tourette syndrome drugs in...
-
Sector Analysis
![]()
Hemophilia A and B – Global Drug Forecast and Market Analysis, 2021-2030
The hemophilia A & B drug market in 8MM was valued at $9.36 billion in 2020 and is expected to grow with a CAGR of more than 4% by 2030. The key driver of growth in the hemophilia A and B markets includes rising life expectancy for hemophilia patients due to reduced morbidity and mortality associated with severe complications and reduced risk of pathogen transmission from plasma-derived sources, increasing the treated population. The US represents the largest market in hemophilia,...
-
Product Insights
![]()
Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Drugs in Development, 2021, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape. Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include...
-
Product Insights
![]()
Dermatomyositis Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Dermatomyositis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Dermatomyositis Clinical trials scenario. This report provides top line data relating to the clinical trials on Dermatomyositis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs...
-
Product Insights
![]()
Primary Immune Deficiency (PID) Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Primary Immune Deficiency (PID) Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Primary Immune Deficiency (PID) Clinical trials scenario. This report provides top line data relating to the clinical trials on Primary Immune Deficiency (PID). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Product Insights
![]()
Dermatomyositis Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Dermatomyositis Global Clinical Trials Review, H2, 2016" provides an overview of Dermatomyositis clinical trials scenario. This report provides top line data relating to the clinical trials on Dermatomyositis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
![]()
Hemophilia A Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Hemophilia A Global Clinical Trials Review, H2, 2016" provides an overview of Hemophilia A clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia A. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
![]()
Fibrinogen Deficiency (Factor I Deficiency) Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Fibrinogen Deficiency (Factor I Deficiency) Global Clinical Trials Review, H2, 2016" provides an overview of Fibrinogen Deficiency (Factor I Deficiency) clinical trials scenario. This report provides top line data relating to the clinical trials on Fibrinogen Deficiency (Factor I Deficiency). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.